Gilead Sciences Stocks Are Up
I’ve been following Gilead Sciences incredibly close recently. It’s hard not to. After all, the company is the leader in HIV and hepatitis C treatments. Although the stock is down a bit this month, I’m not concerned and don’t think you should be either. As a matter of fact, in yesterday’s post, I mentioned that the stock is in a good position for buying long. With that said, we’re seeing movement into the green today. So far (12:12), GILD has gained 1.53% or $1.53 per share and is trading at $101.79 per share.
Outlook – As I mentioned above, Gilead Sciences is not only a great company, they are the world’s leader in treatment providers for major ailments. Not to mention, they continue to innovate every step of the way. With that said, I think we’re going to see long term gains from GILD.
MEI Pharma Is Bouncing Back To Stability
Yesterday was a horrible day for MEI Pharma stock holders. After announcing that the results of clinical trials for an investigative cancer drug yielded poor results. As a matter of fact, the new drug seems to have only negative affects. Nonetheless, there is still testing to be done and the results we heard yesterday that caused the stock to fall by more than 60% may still be misleading. While I don’t think there’s any chance of the stock making up the tremendous losses we saw yesterday, it seems as though the fall has stopped for now and the price is stabilizing. Currently (12:18), MEIP is trading at $2.00 per share after a gain so far today of 3.37% or $0.07 per share.
Outlook – Unfortunately, I don’t see much good news in the future for MEI Pharma stocks. The news yesterday was huge. It told investors that the company has spent millions upon millions of dollars investigating a treatment that seems to have no positive affects. That’s a big miss!
Amarin Stocks Are Back On Uptrends
Amarin stocks have been on a bit of a downtrend over the past few days following big gains after an analyst upgrade. However, as I’ve mentioned in previous posts, I look for long term investment options. With that said, I think Amarin is a great choice. For details as to why I say that, click here! Nonetheless, it looks like the stock is back on uptrends today. Currently (12:40), the stock is trading at $2.54 per share after a gain of 3.53% or $0.09 per share.
Outlook – As mentioned above, I’m expecting great things from Amarin over the long run. A few reasons for this include the fact that the company’s ability to continuously decline their losses…making their way closer and closer to profits. I think this is a great long term choice.
MannKind Stocks Are Climbing Again
MannKind stocks are back on the rise after falling dramatically following an unfounded Goldman Sachs downgrade. For a quick overview, the company’s stock was downgraded as the result of poor sales of Afrezza. However, there are certain factors at play here that say the drug is great, but limit the ability to market it…so far. The reality is that Afrezza seems to be a superior insulin; and no matter how you slice it, that will catch on over time! Currently (12:45), MNKD is trading at $5.24 per share after a gain of 0.48% or $0.03 per share so far today.
Outlook – As mentioned above, I have quite a bit of faith in MannKind’s ability to grow over the long term. However, it is important to remember that in the volatile small-cap tech market, we will see drops here and there. That’s OK, this is still a great long option.
What Do You Think?
Do you have an opinion on any of the stocks mentioned here? We’d love to see it in the comments below!